

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 36922

**Title:** Procalcitonin in inflammatory bowel disease: drawbacks and opportunities

**Reviewer's code:** 02441423

**Reviewer's country:** Iran

**Science editor:** Ke Chen

**Date sent for review:** 2017-10-29

**Date reviewed:** 2017-11-12

**Review time:** 14 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

Dear author, Thank you for your nice review. Unfortunately, due to lack of powerful studies firm recommendation could not be proposed. however, this review could be a start for targeted studies. Best

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 36922

**Title:** Procalcitonin in inflammatory bowel disease: drawbacks and opportunities

**Reviewer's code:** 02997840

**Reviewer's country:** United States

**Science editor:** Ke Chen

**Date sent for review:** 2017-10-29

**Date reviewed:** 2017-11-19

**Review time:** 21 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

The review by Lippi and colleagues deals with the utility of procalcitonin in the diagnosis and management of patients with inflammatory bowel disease. The authors provide a thorough review of the literature dealing with this topic. The manuscript would be improved in the authors provided the following: (i) a discussion in the introduction section as to whether this biomarker is being clinically used or recommended in the diagnosis or management of other inflammatory states; this would be in addition to the information they discuss regarding when procalcitonin is elevated and (ii) a summarizing paragraph at the end of the section titled "Epidemiological studies on procalcitonin in inflammatory bowel disease" detailing when this biomarker would be useful in managing IBD patients.